YWYunfei Wang

Yunfei Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yunfei Wang has a total of 176 co-authors. Here are the top co-authors by number of shared publications:

  • Chunsheng Kang

    Department of Neurosurgery, Tianjin Medical University General Hospital, Laboratory of Neuro-oncology, Tianjin Neurological Institute, Key Laboratory of Post-Neuro Injury Neuro-Repair and Regeneration in Central Nervous System, Ministry of Education and Tianjin City, Tianjin 300052, China

    12 shared publications
  • Chao Yang

    Lab of Neuro-oncology, Tianjin Neurological Institute, Key Laboratory of Post-Neuroinjury Neuro-repair and Regeneration in Central Nervous System, Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, China

    9 shared publications
  • Qixue Wang

    Laboratory of Neuro-oncology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Key Laboratory of Post-Neuro Injury Neuro-Repair and Regeneration in Central Nervous System, Ministry of Education and Tianjin City , Tianjin

    9 shared publications
  • Kaikai Yi

    Department of Neuro-Oncology and Neurosurgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin , Tianjin’s Clinical Research Center for Cancer, Tianjin, China (K.Y.)

    6 shared publications
  • Junhu Zhou

    5 shared publications
  • Kai Huang

    Tianjin Neurological Institute Key Laboratory of Post‐Neurotrauma Neuro‐Repair and Regeneration in Central Nervous System Ministry of Education and Tianjin City Tianjin 300052 China

    5 shared publications

Latest Publications

  • NEU1 sustains mitochondria-lysosome contacts to trigger lysosomal Cu²+/cathepsin escape and mitochondrial lysis in glioblastoma (NeuLysis)

    by Yanping Huang, Dongyuan Su, Xiaoteng Cui, Yaqing Ding, Qi Zhan, Biao Hong, Jixing Zhao, Hanyi Xu, Longtao Cui, Chunchao Cheng, et al.

    Background: Mitochondria-lysosome contacts regulates metabolic reprogramming in cancer, yet its role in glioblastoma pathogenesis remains poorly defined. Methods: We employed an integrated approach, including transmission electron microscopy (TEM) and Hessian-structured illumination microscopy (Hessian SIM), Fluorescence Resonance Energy Transfer-Fluorescence Lifetime Imaging (FRET-FLIM) assays, targeted metabolomics, mitochondrial respiration analyses, subcellular fractionation, and in vivo orthotopic xenograft models. Results: Genetic depletion or pharmacological disruption using EPIC-1042 against PTRF led to NEU1 destabilization via lysosome-dependent degradation, potentiating lysosomal function and prolonging mitochondria-lysosome contacts duration. Within this sustained contact state, dual flux transported from lysosomes to mitochondria: (1) Cu²+, which triggered DLAT aggregation and induced cuproptosis; and (2) cathepsin B, which caused mitochondrial protein degradation. Consequently, morphology and function were destroyed. NEU1 deficiency phenocopied these effects and heightened sensitivity to copper ionophore Elesclomol. Pharmacological inhibition of NEU1 with Oseltamivir synergized potently with Elesclomol to suppress intracranial glioblastoma overall growth and significantly extend survival in vivo. Conclusions: We depict NeuLysis (NEU1-induced Lysosomal Escape leading to mitochondrial Lysis) as a novel cell death pathway in glioblastoma, wherein PTRF-NEU1 axis prolonged mitochondria-lysosome contacts. Pharmacological NEU1 inhibition with Oseltamivir synergizes Elesclomol-induced cell death, providing a preclinically actionable therapeutic strategy against glioblastoma.


  • Open Access

    Linagliptin synergizes with cPLA2 inhibition to enhance temozolomide efficacy by interrupting DPP4-mediated EGFR stabilization in glioma

    by Dongyuan Su, Biao Hong, Shixue Yang, Jixing Zhao, Xiaoteng Cui, Qi Zhan, Kaikai Yi, Yanping Huang, Jiasheng Ju, Eryan Yang, et al.


  • Open Access

    Abstract PO-076: Adrenergic regulation of the anti-tumor immune response in p53-deficient tumors

    by Deborah A. Silverman, Shamima Akhter, Tongxin Xie, Shajedul Islam, Simone Anfossi, Jennifer D. Covello, Frederico O. Gleber-Netto, Elien Doorduijn, Yunfei Wang, Emily L. Ashkin, et al.

    Several previous studies have shown that β2-adrenergic signaling pathway promotes tumor progression, whereas others have shown the opposite effect. The role of β2-adrenergic activation in oral squamous cell carcinoma (OSCC) remains largely unknown. Our previous study showed that the loss of p53 leads to increased adrenergic tumor innervation in OSCC, resulting in transcriptional programs that establish new neuronal identity. We hypothesized that tumor immunity in OSCC is regulated by adrenergic signaling. The aim of the present study was to determine the influences of adrenergic signaling in immune microenvironment of OSCC. We first performed multiplex immunofluorescence to analyze the immune cell infiltration and adrenergic nerve density in OSCC; and analyzed the Cancer Genome Atlas (TCGA) datasets to establish correlations between immune-related and adrenergic pathway genes. Subsequently, we performed T cell killing assay with p53 knockout (KO) and p53 wild-type (WT) using antigen-specific HLA-matched patient-derived T-cells with adrenergic agonists or antagonists. To confirm p53-dependent adrenergic signaling in OSCC, a genetically engineered p53MDM2 overexpression (OE) cell line was generated and treated with adrenergic agonists or antagonists. To test our hypothesis that p53 regulates adrenergic-dependent paracrine signaling between cancer and T cells we performed a Luminex assay on the conditioned medium from p53KO and p53WT coculture system. Finally, in vivo, adrenergic ablation (THflox/flox) and novel murine models of OSCC were used to investigate the effect of adrenergic nerve signaling on immune infiltration and responses to immunotherapy. Our data showed that the increase in adrenergic nerve density was inversely proportional to the infiltration of exhausted T cells. Analysis of the TCGA data revealed that ADRB2 strongly correlated with tumor immune infiltrate genes. Adrenergic agonists treatment induced significantly more apoptosis in the p53KO but not in the p53WT cells; and overexpression of MDM2 rescued the resistance to apoptosis. Conditioned media experiments showed that the coculture of tumor cells with T cells acts through paracrine signaling and that the secreted factor is CXCL10. We then knocked out CXCL10 and ADRB2 in p53KO cells and confirmed that apoptosis was significantly reduced in the absence of CXCL10 or ADRB2. Genetic ablation of adrenergic signaling in vivo undermined response to anti-programmed cell death protein 1 (anti-PD1) compared to controls. Finally, our mouse model of OSCC showed that isoprenaline (β-adrenergic agonist) treatment in combination with PD-1 therapy significantly enhanced response to immunotherapy and improved survival. Our study provides new evidence that adrenergic signaling induces immune-mediated apoptosis and response to immunotherapy. Further studies are needed to assess the role of isoprenaline combined with anti-PD-1 therapy as a novel therapeutic regimen for patients with p53-deficient OSCC tumors. Citation Format: Deborah A. Silverman, Shamima Akhter, Tongxin Xie, Shajedul Islam, Simone Anfossi, Jennifer D. Covello, Frederico O. Gleber-Netto, Elien Doorduijn, Yunfei Wang, Emily L. Ashkin, Jeffrey N. Myers, George A. Calin, Patrick Hwu, Moran Amit. Adrenergic regulation of the anti-tumor immune response in p53-deficient tumors [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-076.

  • Open Access

    Ginsenoside CK induces apoptosis and suppresses proliferation and invasion of human osteosarcoma cells through the PI3K/mTOR/p70S6K1 pathway

    by Kang Chen, Jianbao Jiao, Jinwei Xue, Taoping Chen, Yu Hou, Yuantao Jiang, Ligang Qian, Yunfei Wang, Zheng Ma, Zhixing Liang, et al.

    Osteosarcoma is one of the most malignant bone tumors, and its major threats are aggressive invasion and early tumor metastasis, which result in a poor prognosis and high mortality. Accumulating evidence indicates that ginsenoside compound K (CK) has a significant antitumor effect, particularly on the inhibition of proliferation and invasion of numerous human tumors. In the present study, it was revealed that CK inhibited the viability and proliferation of osteosarcoma cells. Moreover, it was demonstrated that CK induced apoptosis and inhibited the migration and invasion of osteosarcoma cells via apoptotic staining, Annexin V/PI staining, and Transwell invasion assays. Furthermore, at the molecular level, the present results confirmed that apoptosis and invasion‑related proteins were regulated by CK, which was possibly related to the blockade of the PI3K/mTOR/p70S6K1 signaling pathway. In summary, the present findings indicated that CK inhibited viability and proliferation, induced apoptosis, and inhibited the migration and invasion of osteosarcoma cells through the PI3K/mTOR/p70S6K1 signaling pathway.


  • Open Access

    Isoborneol Attenuates Low-Density Lipoprotein Accumulation and Foam Cell Formation in Macrophages

    by Yunfei Wang, Zhengrong Li, Boxue Liu, Rumeng Wu, Haifeng Gong, Zhanhai Su, Shoude Zhang

    Purpose: Isoborneol has been used in the treatment of cardiovascular disease for several years in China. However, the mechanism is still unclear. The aim of this study was to identify the novel mechanism of isoborneol for its application in atherosclerotic disease. Materials and Methods: The whole-genome gene expression profiles of MCF-7 cells treated with/or without isoborneol were detected by mRNA microarray analysis. The degree of similarity between the gene expression profiles was compared with the Connectivity Map (CMAP) database. An MTT assay was used to assess the toxicity of isoborneol on RAW 264.7 cells. Oil red O staining and a Dil-ox-LDL uptake assay in RAW 264.7 cells were also used to detect the accumulation of lipids in the macrophages and the uptake of oxidized low-density lipoprotein (ox-LDL). Results: Isoborneol was proved to have mRNA expression profiles similar to that of ikarugamycin which can inhibit the uptake of ox-LDL. This process has proved to be an important cause of foam cell formation and early atherosclerotic lesions. It is speculated, therefore, that isoborneol may show similar activity to that shown by ikarugamycin. Subsequently, it was shown that RAW 264.7 cells reduced the absorption of ox-LDL and the accumulation of intracellular lipids after treatment with different concentrations of isoborneol. Conclusion: The results indicate that isoborneol inhibits macrophage consumption of ox-LDL, thereby preventing the accumulation of lipids in the macrophages. These results provide evidence for the application of isoborneol in atherosclerotic disease.


  • Open Access

    RUNX1 contributes to the mesenchymal subtype of glioblastoma in a TGFβ pathway-dependent manner

    by Kai Zhao, Xiaoteng Cui, Qixue Wang, Chuan Fang, Yanli Tan, Yunfei Wang, Kaikai Yi, Chao Yang, Hua You, Rui Shang, et al.

    Runt-Related Transcription Factor 1 (RUNX1) is highly expressed in the Mesenchymal (Mes) subtype of glioblastoma (GBM). However, the specific molecular mechanism of RUNX1 in Mes GBM remains largely elusive. In this study, cell and tumor tissue typing were performed by RNA-sequencing. Co-immunoprecipitation (co-IP) and immunofluorescence (IF) were employed to identify members of the RUNX1 transcriptional protein complex. Bioinformatics analysis, chromatin immunoprecipitation (ChIP), and luciferase reporter experiments were utilized to verify target genes. Analyses of The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) verified the expression levels and prognoses associated with RUNX1/p-SMAD3/SUV39H1 target genes. In vivo patient-derived xenograft (PDX) studies and in vitro functional studies verified the impact of RUNX1 on the occurrence and development of GBM. The results showed that RUNX1 was upregulated in Mes GBM cell lines, tissues and patients and promoted proliferation and invasion in GBM in a TGFβ pathway-dependent manner in vivo and in vitro. We found and verified that BCL3 and MGP are transcriptionally activated by p-SMAD3 /RUNX1, while MXI1 is transcriptionally suppressed by the RUNX1/SUV39H1-H3K9me3 axis. This finding offers a theoretical rationale for using molecular markers and choosing therapeutic targets for the Mes type of GBM.


  • NanoRNP Overcomes Tumor Heterogeneity in Cancer Treatment

    by Qi Liu, Jinquan Cai, Yadan Zheng, Yanli Tan, Yunfei Wang, Zhanzhan Zhang, Chunxiong Zheng, Yu Zhao, Chaoyong Liu, Yingli An, et al.

    Tumor heterogeneity has been one of the most important factors leading to the failure of conventional cancer therapies due to the accumulation of genetically distinct tumor-cell subpopulations during tumor development process. Due to the diversity of genetic mutations during tumor growth, combining use of multiple drugs have only achieved limited success in combating heterogeneous tumors. Herein, we report a novel anti-tumor strategy that effectively addresses tumor heterogeneity by using a CRISPR/Cas9-based nanoRNP carrying a combination of sgRNAs. Such nanoRNP is synthesized from Cas9 ribonucleoprotein, any combinations of required sgRNAs, and a rationally designed responsive polymer that endows nanoRNP with high circulating stability, enhanced tumor accumulation, and the efficient gene editing in targeted tumor cells eventually. By carrying a combination of sgRNAs that targets STAT3 and RUNX1, the nanoRNP exhibited efficient gene expression disruptions on a heterogeneous tumor model with two subsets of cells whose proliferations were sensitive to the reduced expression of STAT3 and RUNX1 respectively, leading to the effective growth inhibition of the heterogeneous tumor. Considering the close relationship between tumor heterogeneity and cancer progression, resistance to therapy, and recurrences, nanoRNP provides a feasible strategy to overcome tumor heterogeneity in the development of more advanced cancer therapy against malignant tumors.


  • Open Access

    Single-cell RNA-seq reveals RAD51AP1 as a potent mediator of EGFRvIII in human glioblastomas

    by Qixue Wang, Yanli Tan, Chuan Fang, Junhu Zhou, Yunfei Wang, Kai Zhao, Weili Jin, Ye Wu, Xiaomin Liu, Xing Liu, et al.

    Recent advances in single-cell RNA sequencing (scRNA-seq) have endowed researchers with the ability to detect and analyze the transcriptomes of individual cancer cells. In the present study, 16,128 tumor cells from EGFR wild-type and EGFRvIII mutant cells were profiled by scRNA-seq. Analyses of scRNA-seq data from both U87MG and U87MG-EGFRvIII libraries revealed inherent heterogeneity in gene expression and biological processes. The cells stably expressing EGFRvIII showed enhanced transcriptional activities and a relatively homogeneous pattern, which manifested as less diverse distributions, gene expression levels and functional annotations compared with those of cells expressing the nonmutated version. Moreover, the differentially expressed genes between the U87MG and U87MG-EGFRvIII groups were mainly enriched in DNA replication, DNA repair and angiogenesis. We compared scRNA-seq data with bulk RNA-seq and EGFRvIII xenograft RNA-seq data. RAD51AP1 was shown to be upregulated in all three databases. Further analysis of RAD51AP1 revealed that it is an independent prognostic factor of glioma. Knocking down RAD51AP1 significantly inhibited tumor volume in an intracranial EGFRvIII-positive GBM model and prolonged survival time. Collectively, our microfluidic-based scRNA-seq driven by a single genetic event revealed a previously unappreciated implication of EGFRvIII in the heterogeneity of GBM and identified RAD51AP1 as an oncogene in glioma.


  • Open Access

    Genome‐Wide CRISPR‐Cas9 Screening Identifies NF‐κB/E2F6 Responsible for EGFRvIII‐Associated Temozolomide Resistance in Glioblastoma

    by Kai Huang, Xing Liu, Yansheng Li, Qixue Wang, Junhu Zhou, Yunfei Wang, Feng Dong, Chao Yang, Zhiyan Sun, Chuan Fang, et al.

    Amplification of epidermal growth factor receptor (EGFR) and active mutant EGFRvIII occurs frequently in glioblastoma (GBM) and contributes to chemo/radio‐resistance in various cancers, especially in GBM. Elucidating the underlying molecular mechanism of temozolomide (TMZ) resistance in GBM could benefit cancer patients. A genome‐wide screening under a clustered regularly interspaced short palindromic repeats (CRISPR)‐Cas9 library is conducted to identify the genes that confer resistance to TMZ in EGFRvIII‐expressing GBM cells. Deep sgRNA sequencing reveals 191 candidate genes that are responsible for TMZ resistance in EGFRvIII‐expressing GBM cells. Notably, E2F6 is proven to drive a TMZ resistance, and E2F6 expression is controlled by the EGFRvIII/AKT/NF‐κB pathway. Furthermore, E2F6 is shown as a promising therapeutic target for TMZ resistance in orthotopic GBM cell line xenografts and GBM patient‐derived xenografts models. After integrating clinical data with paired primary–recurrent RNA sequencing data from 134 GBM patients who received TMZ treatment after surgery, it has been revealed that the E2F6 expression level is a predictive marker for TMZ response. Therefore, the inhibition of E2F6 is a promising strategy to conquer TMZ resistance in GBM.


  • Identification of long non-coding RNA HERC2P2 as a tumor suppressor in glioma

    by Chao Yang, Lin Wang, Jia Sun, Jun-Hu Zhou, Yan-Li Tan, Yun-Fei Wang, Hua You, Qi-Xue Wang, Chun-Sheng Kang

    Long non-coding RNAs (lncRNAs) have been reported to play important roles in glioma; however, most of them promote glioma progression. We constructed a competing endogenous (ceRNA) network based on the Chinese Glioma Genome Atlas dataset, and lncRNA hect domain and RLD 2 pseudogene 2 (HERC2P2) is the core of this network. Highly connected genes in the ceRNA network classified the glioma patients into three clusters with significantly different survival rates. The expression of HERC2P2 is positively correlated with survival and negatively correlated with clinical grade. Cell colony formation, Transwell and cell scratch tests were performed to evaluate the role of HERC2P2 in glioblastoma growth. Furthermore, we overexpressed HERC2P2 in U87 cells and established a mouse intracranial glioma model to examine the function of HERC2P2 in vivo. In conclusion, we identified a lncRNA with tumor suppressor functions in glioma that could be a potential biomarker for glioma patients.